Development of autoantibodies in the TrialNet Natural History Study - Wikidata - wikimedia - TriplyDB

Development of autoantibodies in the TrialNet Natural History Study

Development of autoantibodies in the TrialNet Natural History Study

http://www.wikidata.org/entity/Q35179922

about

Evaluation of Candidate Biomarkers of Type 1 Diabetes via the Core for Assay Validation Network for Pancreatic Organ Donors with Diabetes (nPOD): developing a tissue biobank for type 1 diabetes Type 1 diabetes mellitus.HLA-DRB1*15:01-DQA1*01:02-DQB1*06:02 Haplotype Protects Autoantibody-Positive Relatives From Type 1 Diabetes Throughout the Stages of Disease Progression B cells and type 1 diabetes ...in mice and men.Neuronal T-cell autoreactivity is amplified in overweight children with new-onset insulin-requiring diabetes.β cell death and dysfunction during type 1 diabetes development in at-risk individuals.ECL-IAA and ECL-GADA Can Identify High-Risk Single Autoantibody-Positive Relatives in the TrialNet Pathway to Prevention Study.Insulitis in the pathogenesis of type 1 diabetes An important minority of prediabetic first-degree relatives of type 1 diabetic patients derives from seroconversion to persistent autoantibody positivity after 10 years of age.Risk Factors for Type 1 Diabetes Recurrence in Immunosuppressed Recipients of Simultaneous Pancreas-Kidney Transplants.The relationship between BMI and insulin resistance and progression from single to multiple autoantibody positivity and type 1 diabetes among TrialNet Pathway to Prevention participants.Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association.The multiple origins of Type 1 diabetes.Role of B lymphocytes in the pathogenesis of type 1 diabetes.Can we prevent type 1 diabetes?Increasing ICA512 autoantibody titers predict development of abnormal oral glucose tolerance tests.Do Electrochemiluminescence Assays Improve Prediction of Time to Type 1 Diabetes in Autoantibody-Positive TrialNet Subjects?Reversion of β-Cell Autoimmunity Changes Risk of Type 1 Diabetes: TEDDY Study.Oxidative Modifications in Tissue Pathology and Autoimmune Disease.The Role of Age and Excess Body Mass Index in Progression to Type 1 Diabetes in At-Risk Adults.Understanding and preventing type 1 diabetes through the unique working model of TrialNet.Have we pushed the needle for treatment of Type 1 diabetes?B cells in type 1 diabetes mellitus and diabetic kidney disease.Impact of Age and Antibody Type on Progression From Single to Multiple Autoantibodies in Type 1 Diabetes Relatives.HLA-G 14-bp polymorphism affects the age of onset in Type I Diabetes Mellitus.Abnormal T Cell Frequencies, Including Cytomegalovirus-Associated Expansions, Distinguish Seroconverted Subjects at Risk for Type 1 Diabetes β Cell dysfunction exists more than 5 years before type 1 diabetes diagnosis

P2860

Q26783728-D76A2AC7-71BA-4083-B13F-8D4631FA2E87 Q27009104-5ADB45F3-9365-4AE4-81D8-19496876D5DA Q30235021-4291BB6E-28DE-40F9-BA87-079309C0A37A Q30732418-2C0B056D-EB5B-419F-B07D-6F8570E32AF4 Q33926306-171E134A-1EF4-4009-9886-9A2981779E42 Q34762316-7B831021-5564-4CB3-ACDB-F60177590846 Q35183950-134B41DF-9996-4281-8943-A02CAE8B1749 Q37062268-92352B79-0468-4D36-839C-68E12155B001 Q37103789-EAE51E57-1AE4-4D3A-8FE7-2D3ACAFBFA2B Q37261014-2D5EAC7D-0F68-49F9-8A61-88B67EE7A2C1 Q37316533-CC859A5C-F553-47B2-A39C-6F4145206AD0 Q37368421-045B7470-EBC6-4081-B041-AFE44182EAFC Q37659402-4EC92DA2-AF9B-481C-AD51-2AC25D1D92B0 Q38062580-1C7796E5-A79F-4C73-87B7-82D1468105A1 Q38246133-0036D17D-78AD-479C-A118-8F5BDE7755AB Q38586895-9086E751-EDD0-46F7-B970-CDBF05ADF3D2 Q38679602-9622F128-07B5-4A3C-9039-CCBD85CE7579 Q38837965-9B445ACF-A2E6-4A87-AD98-6BD31249B728 Q40954993-DC00CB78-FA3F-4E00-97DA-5D187F0BA0DB Q45989245-67EE7976-8157-46AF-997D-A4EAFF9E3A9E Q46140989-99479AB9-A078-45F3-BCD8-B2E896462D9F Q46486153-BC0F4CAF-BA59-4D3E-9B54-7092A8D8C83F Q47907621-B085C114-12FF-4B39-A7D5-DC3585DAB1F9 Q50077505-7F84AA61-6188-436F-8204-0781F76DFD16 Q50988456-B666865A-90CE-4E81-B209-7FD6FEDCC514 Q53121646-486ADA6C-7077-4721-BFF0-5CEC783488D5 Q58580465-4E473178-8170-4912-9CEC-5C984106F22F Q58792346-66A474BA-C3BA-42C7-AE21-C9264B8C2637

P2860

Development of autoantibodies in the TrialNet Natural History Study

http://www.wikidata.org/entity/Q35179922

description

2011 nî lūn-bûn

@nan

2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Development of autoantibodies in the TrialNet Natural History Study

@ast

Development of autoantibodies in the TrialNet Natural History Study

@en

type

label

Development of autoantibodies in the TrialNet Natural History Study

@ast

Development of autoantibodies in the TrialNet Natural History Study

@en

prefLabel

Development of autoantibodies in the TrialNet Natural History Study

@ast

Development of autoantibodies in the TrialNet Natural History Study

@en

P1433

Q35179922-939194DA-354D-44C9-9043-215EA6B18318

P1476

Q35179922-54CD0553-1A69-42BC-8666-01EA7D0EC0A5

P2093

Q35179922-639C31A3-8E31-4A48-9274-116359334F99

Q35179922-702E6B34-A626-48AE-81A3-EEEAC36E7F50

Q35179922-76020DCC-A756-4E68-A074-3AF1DDB29667

Q35179922-76CCF605-975D-41A4-9C4D-B48D6729EC50

Q35179922-770CF316-F080-4A19-BE9D-EDA89A6CD0AB

Q35179922-8128A340-B3F0-4613-8031-19E450C23AA6

Q35179922-8A7342A7-7A9C-43A3-894C-622AA88854AD

Q35179922-FB2BD170-E1C7-439E-9D9D-9E948BDFF573

P2860

Q35179922-118B46AA-F042-448C-9CB0-E43F49F732FE

Q35179922-14AE83EB-1C88-4D48-9D59-07FBF9ABD813

Q35179922-23085A5A-443F-4C57-A303-2762CCC28836

Q35179922-540BDF77-13E2-4BAA-96A6-36EA667CA328

Q35179922-64B485E7-882E-480E-A94B-451BF3517BC6

P304

Q35179922-DE3587C5-E010-47A9-9BB3-AFCE5BB37535

P31

Q35179922-87440A89-5A2F-417B-A1A3-5CF20528DF82

P356

Q35179922-13EF32D1-5035-4F8C-9F6F-C6EB5E3782B9

P407

Q35179922-4016CF15-7FA9-4E4A-90A5-E378BEC8F245

P433

Q35179922-63E00459-5976-4A0C-90C7-96299FC705B0

P478

Q35179922-CEFA9937-6670-4E6D-8632-38BAFDF4A36C

P50

Q35179922-01BA3A06-6CE0-4F18-A371-81B0F6855F56

P577

Q35179922-AC75C8B9-A999-4D5C-82B4-4BB36B525D69

P5875

Q35179922-1ABBD4EB-3727-46EF-AD66-C875BF3719F5

P698

Q35179922-243A098B-59D5-41BB-9947-A15D9A8E9907

P921

Q35179922-CFD5940A-F523-4162-BCBE-02081D406759

P932

Q35179922-DEAA455A-E148-4EE5-AEA2-E41624AD5244

P356

P1433

P1476

Development of autoantibodies in the TrialNet Natural History Study

@en

P2093

Craig A Beam

http://www.w3.org/2001/XMLSchema#string

Desmond A Schatz

http://www.w3.org/2001/XMLSchema#string

Jay M Sosenko

http://www.w3.org/2001/XMLSchema#string

Jay S Skyler

http://www.w3.org/2001/XMLSchema#string

Jeffrey L Mahon

http://www.w3.org/2001/XMLSchema#string

Jeffrey P Krischer

http://www.w3.org/2001/XMLSchema#string

Michael J Haller

http://www.w3.org/2001/XMLSchema#string

TrialNet Natural History Study Group

http://www.w3.org/2001/XMLSchema#string

P2860

Prediction of type 1 diabetes in the general population.

Islet cell antibodies predict insulin-dependent diabetes in United States school age children as powerfully as in unaffected relatives.

Islet autoantibody seroconversion in the DPT-1 study: justification for repeat screening throughout childhood.

The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results.

Early environmental events as a cause of IDDM. Evidence and implications.

P304

1897-1901

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DC11-0560

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

34

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-07-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51486767

http://www.w3.org/2001/XMLSchema#string

P698

21750277

http://www.w3.org/2001/XMLSchema#string

P921

P932

3161292

http://www.w3.org/2001/XMLSchema#string